0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Efficacy and safety of tolvaptan in heart failure patients with volume overload.

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

           Loop diuretics are commonly used in heart failure (HF) patients, but they are sometimes associated with insufficient response as well as adverse events. In such diuretics-resistant cases, tolvaptan, a vasopressin type 2 receptor antagonist, shows the improvement of volume overload without electrolyte imbalance. Tolvaptan was launched in Japan in 2010, and a post-marketing surveillance has been performed to evaluate the safety and efficacy of tolvaptan in real-world clinical settings.

          Related collections

          Author and article information

          Journal
          Circ. J.
          Circulation journal : official journal of the Japanese Circulation Society
          1347-4820
          1346-9843
          2014
          : 78
          : 4
          Affiliations
          [1 ] Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. kinugawa-tky@unin.ac.jp
          Article
          DN/JST.JSTAGE/circj/CJ-14-0126
          24670835
          5ee5cea6-a9fe-4a5c-bde0-e3e9e2e7e869
          History

          Comments

          Comment on this article